Humana Touts Success of Its Wellness Program

Humana says that 50,000 of its employees are ahead of schedule when it comes to achieving their wellness goals, according to a Humana progress report. The company’s wellness program, Bold Goal, set certain benchmarks it wants participating employees to reach by 2020. Those 50,000 workers are actually going to meet the goals by the end of this year. Participation is key, and even that’s looking better, according to the insurer. Since the launch of Bold Goal in 2012, the employee engagement rate for the wellness program rose from 28% to 80%.

Humana officials liked what they saw so much that they began offering it to Humana beneficiaries in seven communities. They are located in Louisiana, Tennessee, Florida, Texas, and Kentucky. The CDC’s health management tool Healthy Days is used to measure progress. The program takes “into account how a person is feeling holistically, including his or her mental and physical health,” the company said in a press release (link is external).

The report states that “we have learned a lot about the social determinants of health and what impacts health outcomes. Through our work with local nonprofit, business and government organizations, as well as physicians, we continue to improve the health of our communities, Humana members and our associates (employees).”

San Antonio was the first Bold Goal community, and experienced a 9% decrease in the number of “unhealthy days,” thanks to the program’s focus on food insecurity and behavioral health services. “Through a telepsychiatry pilot program and food insecurity screening implemented in primary care offices, these health barriers were directly addressed,” Humana said. “Improvements in diabetes management were also achieved through collaboration between Humana, the San Antonio Health Advisory Board and the American Diabetes Association.”

Source: 2017 Progress Report: Bold Goal, Humana (link is external)

More Headlines

Single-Tablet Dolutegravir / Rilpivirine Regimen Submitted to FDA

First two-drug HIV maintenance treatment

Why Antibiotics Fail

Biologists seek to correct flaw in how bacterial susceptibility is tested

As Government-Funded Cancer Research Sags, Scientists Fear U.S. Is Losing Its Edge

Trump budget aims to cut $1 billion from NCI

Conservative Groups Push HHS Secretary Price to Help Dismantle PPACA

Price urged to wield regulatory powers as senators flounder

New Health Care Plan Unlikely This Year, Republican Senator Says

Conservative and centrist GOP lawmakers continue to butt heads

Researchers Develop New Drug-Delivery Strategy for Pain Relief

“Game-changing” approach targets receptors inside nerve cells

FDA Approves Rebinyn for Adults and Children With Hemophilia B

Product launch expected in first half of 2018

Study: More Than Half of Cancer Patients’ Emergency Department Visits Appear Preventable

Findings represent rare opportunity to reduce costs and improve patient outcomes, authors say

HHS: Mylan May Have Overcharged U.S. for EpiPen by $1.27 Billion

Amount is three times more than company agreed to repay

Basaglar is coming on the scene during tumultuous times for insulin products. Manufacturers are under attack for price hikes. There are allegations of backroom rebate deals. And a class-action lawsuit has been brought on behalf of uninsured patients, charging insulin makers with setting artificially high prices.

Telehealth: Some Thumbs Up, Some Down, On Quality of Care

Evaluating the quality of telemedicine care is about as easy as evaluating the quality of health care, period, and researchers are still ironing out the methodological kinks. That may be one reason research results are all over the place. This article involved reviewing nine such studies, and the findings are a mixed bag.

Real-World Evidence Faces Some Real-World Challenges

RWE is a relatively new kid on the block. How exactly it will fit into the complicated world of cancer drug testing, approval, regulation, and marketing is uncertain. The randomized clinical trial has been the gold standard in oncology research for decades and will remain so for the foreseeable future.

Telehealth Wave: Surf’s Up for Fed, State Policymakers

If millions of Americans lose Medicaid or private health insurance coverage because of the unACAing of American health care, telehealth may seem like a gimmicky sideshow rather than a good-faith effort to bring health care into the digital century.

A Conversation with Henry DePhillips, MD: The Doctor in the Teladoc House

The CMO of Teladoc, one of the country’s largest telemedicine providers, certainly knows how to sing the praises of the industry, and handle devil’s advocate kind of questions as well. Most of Teledoc’s customers are commercial insurers and employers. Medicare? Not so much. Medicaid makes “perfect sense.”

Are Insurers’ Prior Authorization Rules Killing Opioid Addicts?

The results can be tragic. Patients with addictions are unlikely to wait the hours or days it takes health insurers to approve the medications they need. Insurers are changing their practices, but not without some outside pressure.

FDA Approves Tymlos for Osteoporosis in Postmenopausal Women

The FDA has given the green light to abaloparatide subcutaneous injection (Tymlos, Radius Health) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed on or are intolerant of other available osteoporosis therapy.

‘Telemental’ Health Is Becoming the Norm

One area where more research is needed is on programs that mix telemental health with traditional treatment, because in many instances a combination of the two will work better than a steady diet of either. The use of telemental health as an alternative or a backup needn’t be saved for emergencies.

Telehealth Business: Boom Times, but Profits May Wait

What we have here is irrational telehealth exuberance. Investors are plowing millions into startups. And even though millennials could be eager adopters, these are still early days for the industry. It may take years—and some regulatory changes—for profits to materialize.

Facing the Opioid Crisis: Scientists Search for Less-Addictive Alternatives

Approximately two million Americans are hooked on prescription opioids or heroin, and an overdose of pain pills kills 91 people every day. Approximately 20 years ago, pharma companies invested heavily in alternative treatments and “failed miserably,” Dr.

Paul Lendner

Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.

More Headlines

Read Next